An integrated system for diagnosing neoplasms with the help of artificial intelligence is undertaken by a joint venture of ISTOMEDICA, WITSIDE & Synergy Value.
The project, called AI-PathoLab, is funded by the Special Service for Management and Implementation of Actions in the Sector of Research, Technological Development and Innovation (EYDE-ETAK) of the Ministry of Development and Investment in the framework of the Research-Creative-And action. It has a budget of € 441,030.00 and a total duration of 30 months.
The project is expected to contribute substantially to:
More specifically, the AI-PathoLab platform utilizes the capabilities of Artificial Intelligence to:
Mr. Christos Papadopoulos, CEO of WITSIDE and Scientific Officer of the Project, told us: “People are entitled to more accurate diagnoses and targeted treatments at low cost. In this project, we combine interdisciplinary knowledge and skills to improve the lives of patients and their families. "
Mr. Nikos Goutas, Doctor of Pathology, Associate Professor of NTUA and co-owner of Istomedica stated: "Through AI-PathoLab, we aim to provide young physicians with high-level know-how, as well as a powerful digital tool that will help in the valid and timely diagnosis of neoplasms."
The Commercial Director of Synergy Value, Mr. Giannis Syrimpeis stated: “At Synergy Value our interest in innovative applications and cutting-edge technologies is intense. AI-PathoLab combines our passion for new solutions, our experience in healthcare applications and the hope of enhancing medical diagnostic tools.”